London, UK – April 15, 2016
Who: Pfenex Chief Medical Officer Hubert C. Chen, M.D.
What: Case Study Presentation at 4th Annual Biosimilars & Biobetters Congress
When: Tuesday, April 19, 2016 at 16.00 – 16.30 GMT
Where: Novotel London West Hotel, 1 Shortlands, London, W6 8DR, United Kingdom
Why: Dr. Hubert Chen, M.D., Chief Medical Officer of biosimilars company Pfenex, will present a case-study example illustrating best practices in clinical development for a biosimilar candidate to Interferon beta-1b for the treatment of multiple sclerosis.
Pfenex Inc. (NYSE: PFNX) is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value, and difficult-to-manufacture, proteins. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis® (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfenex Expression Technology® platform to build a pipeline of product candidates under development including other biosimilars, as well as vaccines, generics, and next-generation biologics. For additional information, visit Pfenex.com and connect with us on Twitter @Pfenex.
Note: All trademarks mentioned herein are property of their respective owners.
Media contact: Michelle Ragsdale, Pfenex | Direct (858) 352-4391 | firstname.lastname@example.org